New HIV drug LP-98 tested in humans for first time

NCT ID NCT05933824

Completed Knowledge-focused Sponsor: Shanxi Kangbao Biological Product Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This first-in-human study tested a single dose of LP-98 injection in 36 healthy adults to see if it is safe and how the body processes it. Participants received either LP-98 or a placebo by injection under the skin or into a vein. The study is complete, but it only looked at safety and immune response, not whether LP-98 can prevent or treat HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-98 injection
What this could lead to: If successful, this early research could pave the way for a new HIV prevention or treatment option.
What could go wrong: This is a very early, small trial in healthy people, not those with HIV. It only checks safety and dosing, not whether LP-98 works against the virus. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV (HUMAN IMMUNODEFICIENCY VIRUS)

Contacts and locations

Locations

Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.